Pioneering Pathways: Evolving Use of Neurofilaments in Neurodegenerative Disease

Neurofilaments (NFL) are structural proteins, released into interstitial fluid (CSF and blood) following **axonal damage or neuronal degeneration**^{1,2}

NFL levels may be particularly elevated in some individuals with
neurodegenerative diseases such as ALS and SMA^{3,4}

NFL in SMA




Figure is for illustrative purposes only

NFL levels may be prognostic for disease severity and response to treatment^{1,5}

In infants and younger children with SMA, NFL levels have been shown to be:⁴

- Elevated, reflecting neuroaxonal damage that is central to the disease
- Prognostic for disease severity and responsive to treatment

!

NFL levels in adolescents and adults with SMA may be similar to those without SMA¹

NFL levels are higher in people with:¹

- A more severe disease phenotype (infantileonset vs later-onset SMA)
- Two vs more than three SMN2 copies

Potential utility of NFL levels in SMA^{a,4,6}



Risk/susceptibility marker

NFL could potentially be used for monitoring of genetically at-risk individuals



Prognostic marker

NFL levels could help monitor disease course and inform treatment decision-making



Pharmacodynamic marker

NFL levels may have utility for monitoring response to treatment in younger people with SMA who have two *SMN2* copies

Considerations for use of NFL:


- Use is well-studied in young children with two SMN2 copies, but not in adolescents and adults with SMA
- Sample collection from infants remains challenging (e.g. due to blood volume requirements)

ALS, amyotrophic lateral sclerosis; CSF; cerebrospinal fluid; SMA, spinal muscular atrophy.

^a More research is needed to better understand potential utility of NFL levels in SMA; currently NFL levels are most well-established for use in clinical research/population level rather than for use on the patient level.

1. Yuan Å, et al. *Cold Spring Harb Perspect Biol.* 2017;9(4):a018309; 2. Verde F, et al. *Front Neurosci.* 2021;15:679199; 3. Witzel S, et al. *Ann Neurol.* 2024;96(6):1040-1057; 4. Bayoumy S, et al. *Clin Chem Lab Med.* 2024;62(7):1252-1265; 5. Giorgia Q, et al. *Front Neurol.* 2023;14:1226969; 6. Glascock J, et al. *J Neuromuscul Dis.* 2023;10:937-954.

Pioneering Pathways: Evolving Use of Neurofilaments in Neurodegenerative Disease



Use of NFL in ALS clinical trials^{2–4}



Risk/susceptibility marker

For predicting phenoconversion to clinically manifest disease in at-risk mutation carriers



Prognostic marker

As a marker of disease progression and survival, and to control for the heterogeneity of disease progression



Pharmacodynamic marker For monitoring response to treatment



Clinical trial only Safety marker Indication of potential neurotoxity

NFL level use in clinical settings is limited by:

- Being a nonspecific marker of axonal injury
- Results from different platforms cannot be compared due to the lack of established reference values used reliably across the field

ALS, amyotrophic lateral sclerosis; NFL, neurofilaments

1. Benatar M, et al., *Brain*. 2023; 146(7):2711–2716; 2. van den Berg LH, et al. *Neurology*. 2019;92(14):e1610-e1623; 3. Benatar M, et al. *Ann Neurol*. 2024;95(2):211-216; 4. Yuan A, Nixon RA. *Front Neurosci*. 2021;15:689938.